Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus
New Appointment at Nkarta: Nkarta, Inc. has appointed Dr. Shawn Rose as Chief Medical Officer and Head of R&D, effective June 23, 2025, succeeding Dr. David R. Shook who is leaving to pursue opportunities in oncology.
Focus on NK Cell Therapies: Dr. Rose brings extensive experience in immunology and translational medicine, aiming to advance Nkarta's allogeneic NK cell therapies for autoimmune diseases, particularly through the development of their candidate NKX019.
Trade with 70% Backtested Accuracy
Analyst Views on NKTX
About NKTX
About the author
ImmunityBio Shares Triple in Three Weeks, Short-Sellers Face $500 Million Loss
- Price Surge: ImmunityBio's stock price has tripled over three weeks, closing at $6.92 on Wednesday with a 6.79% increase, indicating strong market interest in its immunotherapy developments, potentially attracting more investors.
- Volume Spike: Trading volume reached 93.5 million shares on Wednesday, about 357% above the three-month average of 20.5 million shares, signaling a significant rise in investor attention that could lead to further price volatility.
- Short-Seller Losses: With 35% of the public float held short, short-sellers now face nearly $500 million in paper losses, reflecting optimistic market sentiment towards ImmunityBio's future developments, which may prompt short-covering to mitigate losses.
- Market Reaction: Although there was no specific news driving the price increase, the actions of short-sellers covering their positions combined with recent positive developments have contributed to the stock's rise, showcasing ongoing interest in the biotechnology sector.
Nkarta (NKTX) Participates in Evercore 8th Annual Healthcare Conference to Showcase NK Cell Therapy Progress
- Conference Participation: Nkarta will participate in the Evercore 8th Annual Healthcare Conference on December 4 in Miami, showcasing its progress in NK cell therapies for autoimmune diseases, which is expected to attract investor and industry attention.
- Live Webcast: The event is scheduled for 10:50 a.m. ET and will be simultaneously webcast on Nkarta's investor section of its website, allowing global investors to access real-time information.
- Replay Availability: Following the conference, a replay will be archived on Nkarta's website for approximately 90 days, ensuring that investors who cannot attend live can still access relevant information, thereby enhancing the company's transparency.
- Company Background: Nkarta focuses on developing allogeneic, off-the-shelf NK cell therapies, combining cell expansion and cryopreservation platforms to provide deep therapeutic activity intended for broad outpatient access, demonstrating its innovative potential in the biopharmaceutical sector.
Nkarta to Attend Investor Conferences in November
Investor Conferences Participation: Nkarta, Inc. will participate in the Stifel 2025 Healthcare Conference on November 12 and the TD Cowen's Immunology & Inflammation Summit on November 13, 2025, featuring fireside chats at both events.
Webcast Availability: A simultaneous webcast of the events will be available on Nkarta's website, with a replay archived for approximately 90 days.
Company Overview: Nkarta is a clinical-stage biopharmaceutical company focused on developing engineered natural killer (NK) cell therapies for autoimmune diseases, utilizing advanced cell engineering and CRISPR technologies.
Contact Information: For media and investor inquiries, Nadir Mahmood from Nkarta can be contacted via email at nmahmood@nkartatx.com.
Nkarta to Present Poster at the Upcoming American College of Rheumatology (ACR) Convergence Meeting
Nkarta's Presentation at ACR Convergence 2025: Nkarta, Inc. will present clinical data on its investigational therapy NKX019 at the American College of Rheumatology meeting, showcasing its effectiveness in depleting pathogenic B cells in non-Hodgkin lymphoma and autoimmune disease models.
Potential of NKX019: The data suggest that NKX019 could serve as a novel therapeutic approach for autoimmune diseases driven by pathological B cells, offering a treatment option with reduced toxicities compared to current therapies.
Details of the Presentation: The poster presentation is scheduled for October 26, 2025, from 10:30 AM to 12:30 PM CT, and will be held in Hall F1, focusing on B Cell Biology & Targets in Autoimmune & Inflammatory Disease.
Company Overview: Nkarta is a clinical-stage biotechnology company specializing in allogeneic NK cell therapies for autoimmune diseases, aiming to provide accessible outpatient treatment options through advanced cell engineering technologies.
Nkarta Posts Narrower Loss in Q2
Financial Performance: Nkarta reported a net loss per share of $(0.31), better than analyst expectations, with operating expenses declining and cash reserves at $334 million, sufficient to fund operations into 2029.
Clinical Trials Update: The company is focused on advancing its lead product candidate NKX019 through ongoing clinical trials (Ntrust-1 and Ntrust-2) for autoimmune diseases, with preliminary data expected in the second half of 2025, while no new efficacy or safety data was released this quarter.
Needham Reiterates Buy on Nkarta, Maintains $10 Price Target
Fastest News Alerts: Benzinga Pro offers real-time intelligence and news alerts to help traders stay informed and make winning trades in the stock market.
Exclusive Community Access: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and insights from Benzinga reporters.
ImmunityBio Shares Triple in Three Weeks, Short-Sellers Face $500 Million Loss
- Price Surge: ImmunityBio's stock price has tripled over three weeks, closing at $6.92 on Wednesday with a 6.79% increase, indicating strong market interest in its immunotherapy developments, potentially attracting more investors.
- Volume Spike: Trading volume reached 93.5 million shares on Wednesday, about 357% above the three-month average of 20.5 million shares, signaling a significant rise in investor attention that could lead to further price volatility.
- Short-Seller Losses: With 35% of the public float held short, short-sellers now face nearly $500 million in paper losses, reflecting optimistic market sentiment towards ImmunityBio's future developments, which may prompt short-covering to mitigate losses.
- Market Reaction: Although there was no specific news driving the price increase, the actions of short-sellers covering their positions combined with recent positive developments have contributed to the stock's rise, showcasing ongoing interest in the biotechnology sector.
Nkarta (NKTX) Participates in Evercore 8th Annual Healthcare Conference to Showcase NK Cell Therapy Progress
- Conference Participation: Nkarta will participate in the Evercore 8th Annual Healthcare Conference on December 4 in Miami, showcasing its progress in NK cell therapies for autoimmune diseases, which is expected to attract investor and industry attention.
- Live Webcast: The event is scheduled for 10:50 a.m. ET and will be simultaneously webcast on Nkarta's investor section of its website, allowing global investors to access real-time information.
- Replay Availability: Following the conference, a replay will be archived on Nkarta's website for approximately 90 days, ensuring that investors who cannot attend live can still access relevant information, thereby enhancing the company's transparency.
- Company Background: Nkarta focuses on developing allogeneic, off-the-shelf NK cell therapies, combining cell expansion and cryopreservation platforms to provide deep therapeutic activity intended for broad outpatient access, demonstrating its innovative potential in the biopharmaceutical sector.
Nkarta to Attend Investor Conferences in November
Investor Conferences Participation: Nkarta, Inc. will participate in the Stifel 2025 Healthcare Conference on November 12 and the TD Cowen's Immunology & Inflammation Summit on November 13, 2025, featuring fireside chats at both events.
Webcast Availability: A simultaneous webcast of the events will be available on Nkarta's website, with a replay archived for approximately 90 days.
Company Overview: Nkarta is a clinical-stage biopharmaceutical company focused on developing engineered natural killer (NK) cell therapies for autoimmune diseases, utilizing advanced cell engineering and CRISPR technologies.
Contact Information: For media and investor inquiries, Nadir Mahmood from Nkarta can be contacted via email at nmahmood@nkartatx.com.
Nkarta to Present Poster at the Upcoming American College of Rheumatology (ACR) Convergence Meeting
Nkarta's Presentation at ACR Convergence 2025: Nkarta, Inc. will present clinical data on its investigational therapy NKX019 at the American College of Rheumatology meeting, showcasing its effectiveness in depleting pathogenic B cells in non-Hodgkin lymphoma and autoimmune disease models.
Potential of NKX019: The data suggest that NKX019 could serve as a novel therapeutic approach for autoimmune diseases driven by pathological B cells, offering a treatment option with reduced toxicities compared to current therapies.
Details of the Presentation: The poster presentation is scheduled for October 26, 2025, from 10:30 AM to 12:30 PM CT, and will be held in Hall F1, focusing on B Cell Biology & Targets in Autoimmune & Inflammatory Disease.
Company Overview: Nkarta is a clinical-stage biotechnology company specializing in allogeneic NK cell therapies for autoimmune diseases, aiming to provide accessible outpatient treatment options through advanced cell engineering technologies.
Nkarta Posts Narrower Loss in Q2
Financial Performance: Nkarta reported a net loss per share of $(0.31), better than analyst expectations, with operating expenses declining and cash reserves at $334 million, sufficient to fund operations into 2029.
Clinical Trials Update: The company is focused on advancing its lead product candidate NKX019 through ongoing clinical trials (Ntrust-1 and Ntrust-2) for autoimmune diseases, with preliminary data expected in the second half of 2025, while no new efficacy or safety data was released this quarter.
Needham Reiterates Buy on Nkarta, Maintains $10 Price Target
Fastest News Alerts: Benzinga Pro offers real-time intelligence and news alerts to help traders stay informed and make winning trades in the stock market.
Exclusive Community Access: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and insights from Benzinga reporters.
